Investment report on Idenix Pharmaceuticals

Apr 16 2010

StockPreacher.com announces an investment report featuring Idenix Pharmaceuticals Inc. (Nasdaq:IDIX). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

Idenix Pharmaceuticals Inc. (IDIX) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe. The Company primarily focuses its research and development on the treatment for hepatitis C virus (HCV). The Company develops nucleoside/nucleotide polymerase inhibitors, including IDX184, a liver-targeted nucleotide prodrug candidate, which is in phase IIa clinical trial; and IDX102 that completed late-stage preclinical development. It also develops IDX375, a novel palm-binding polymerase inhibitor that is in phase I program; IDX320, a protease inhibitor candidate, which is in phase I healthy volunteer clinical study; and NS5A inhibitors.

Message Board Search for IDIX: http://www.boardcentral.com/boards/IDIX

In the report, the analyst notes:

"IDIX shares surged recently following the Company's announcement regarding its interim data from a 14-day, phase IIa clinical trial evaluating its prospective hepatitis C drug IDX-184. According to the data presented at the 45th annual meeting of the European Association for the Study of the Liver being held in Vienna, Austria, a 100-milligram dose of the drug prompted antiviral activity after 14 days of treatment in patients during a mid-stage study.

"As stated by Douglas Mayers M.D., IDIX's executive vice president and chief medical officer, the Company believes that with the favorable antiviral activity, safety and resistance profile seen to date, IDX184 could be a potential component of future direct-acting antiviral combination regimens. Dr. Mayers said the Company is moving ahead with dosing on a 150-milligram version of the drug, and looks forward to reporting full data later this year."